Nasdaq GlobeNewswire

OLYMPUS LABS LAUNCHES PRE-ICO BRINGING A NEW FINANCIAL ECOSYSTEM TO THE BLOCKCHAIN WORLD

Del

New York, NY, Nov. 29, 2017 (GLOBE NEWSWIRE) -- As blockchain and cryptocurrency companies continue to raise millions of dollars in funding, there's an urgent need in the market for companies and investors to be able to better manage its cryptocurrency assets with hedging products and tools. Olympus Labs believes that by offering financial tools and protocol, crypto- based companies and investors will be able to have more control by protecting their downside risk in an otherwise extremely volatile market.

"Olympus Labs is an integrator of cryptocurrency-based financial products (e.g., indices, ETFs, options, futures, etc.). Olympus, third-party financial product developers, and Fintech applications build the products which include but are not limited to exchanges, market analytics tools, payment services, etc. (e.g., Kyber, Shapeshift, Sentiment)," explains Kai Chen, CEO of Olympus Labs.

On November 27, 2017 due to the high demand from outside investors Olympus Labs opened its doors for its Pre-ICO token sale.

The Olympus product is viable and has huge long-term potential. As for competition, it fills an evidently empty space in the cryptocurrency market, practically guaranteeing that Olympus' offerings will be used-and that this usage will generate profits. Olympus's mission is to "define the protocol for crypto-based derivatives," and it seems clear that these products will help mature the market beyond the current spot market.

The first of Olympus's products will allow one to borrow and lend bitcoin. Cryptocurrency index funds will be the second Olympus product to hit the market. These index funds will allow investors to buy into multiple cryptocurrencies at once, with profits moving with the market as a whole instead of with individual spot cryptocurrencies. Through customizable fintech-focused smart contracts, exchanges will be able to quickly and easily make their own indices which track the overall trend of cryptocurrencies traded on that exchange.

To Participate in the Pre-ICO

The Olympus Labs Token Sale started at 8 pm (GMT+8/UTC 12pm), 27 November 2017, and ends at 8pm (GMT+8/UTC 12 pm), 3 December 2017.Olympus Presale terms: Investors contributing more than 100 ETH, will get 10% bonus (1 ETH = 677 Olympus tokens). This will take place after ICO, and those who passed the KYC process, will be issued MOT, the rest who failed in KYC, will be refunded with ETH. For additional information and terms of the sale please visit the Olympus Labs website.

During the registration period (27 November 2017 to 3 December 2017), please visithttps://kyc.olympuslabs.io/.

Note: Information regarding the token sale will ONLY be disseminated on our official communication channels: our official website and our official telegram group.

About OLYMPUS LABS

Olympus is led by a cohesive team with extensive expertise in both the traditional financial markets and blockchain technology. Olympus Founder and CEO Kai Chen started his career on Wall Street with Morgan Stanley, and he later went on to work for McKinsey and PIMCO. Our development team includes Google's former development community lead for China. On the business side, we have Danielle Sabrina, a highly sought-after marketing expert and veteran of several successful ICOs, and has helped her clients achieve prestigious awards such as Inc 500, Forbes Next Billion Dollar Startup, Entrepreneur 360 among other top level recognition. Danielle's work has also been featured in Huffington Post and Entrepreneur. Olympus also has a strong advising board made up of former executives at Morgan Stanley and McKinsey.

OLYMPUS LABS Social Media

For more information about Olympus Labs and the launch of the pre-ICO, please visit https://olympuslabs.io/web; on Twitter @olympuslabsbc and Telegram at https://t.me/olympuslabs.

###

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a88937da-05db-437e-92f0-07cc02b4dd8f

Danielle Sabrina
Olympus Labs
pr@oympuslabs.io

Sharde' Brown
What Vibes Your Tribe
press@wvytmedia.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: OLYMPUS LABS via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

World Conference on Lung Cancer Monday Press Conference: Clinical Research Results and Gender Differences in Lung Cancer Survival24.9.2018 20:26Pressemelding

TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- At today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC), conference co-president Dr. Andrea Bezjak, M.D., FRCPC, MSc, professor in the Departments of Radiation Oncology and Health Policy, Management and Evaluation at the University of Toronto and staff radiation oncologist at Princess Margaret Cancer Centre, summarized the wide-ranging study topics presented in today’s conference, from significant clinical research findings to gender differences in lung cancer survival. IMpower132 study shows atezolizumab in combination with carboplatin and pemetrexed improves survival in Stage IV non-squamous NSCLC Recent findings from the IMpower132 study, presented by Vassiliki A. Papadimitrakopoulou, M.D., chief of the Section of Thoracic Medical Oncology at MD Anderson Cancer Center, demonstrate that the use of atezolizumab in combination with carboplatin as first-l

Bombardier CRJ Series Certified for Higher Maintenance Intervals24.9.2018 18:00Pressemelding

MONTREAL, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft announced today that the Federal Aviation Agency (FAA) has granted approval for the maintenance intervals escalation of the CRJ700, CRJ900 and CRJ1000 aircraft. The line maintenance interval (A-check) is extended to 800 flight hours, and the heavy maintenance interval (C-check) at 8,000 flight hours. “With the longest maintenance intervals on the regional jet market, the CRJ aircraft family continues to deliver more value to operators, along with its excellent reliability and its proven outstanding operational capability”, said Charles Comtois, Head of CRJ Series Program, Bombardier Commercial Aircraft. “We are thrilled that our operators are benefitting from our continuous improvement mindset as with this evolution, the CRJ Series operators can now take advantage of 14 per cent less maintenance days, meaning more days of revenue flying.” The maintenance intervals have doubled since the launch of the CRJ aircra

Mitratech Launches Latest TeamConnect ELM Innovations at Interact24.9.2018 16:01Pressemelding

Full Integration of TAP Workflow Automation, New Business Intelligence Module and Deeper MS Office Integration Enhance Collaboration and Reporting AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Mitratech released the next version of TeamConnect at Interact, the company’s customer-focused annual event in Austin. The latest version of the award-winning ELM platform now includes: Full Integration with TAP Workflow Automation Business Intelligence reporting Deeper Microsoft® Office integration Today, TeamConnect integrates with TAP Workflow Automation and redefines every aspect of data analytics and reporting through the TeamConnect Business Intelligence (BI) module. With the addition of the TAP Workflow Automation Platform recently acquired in April, Mitratech’s TeamConnect platform can now bring people, processes, and information together like never before, by leveraging TAP’s easy-to-use workflow automation engine to extend TeamConnect’s reach across the entire enterprise. TAP was des

Colliers International Appoints Christopher Galvin to Its Board of Directors24.9.2018 16:00Pressemelding

TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI) (“Colliers”) today announced the appointment of Mr. Christopher Galvin to its Board of Directors, effective immediately. Mr. Galvin previously served as the Chairman and co-founder of Harrison Street Real Estate Capital LLC, one of the largest real estate investment firms dedicated to the education, healthcare and storage sectors. Colliers acquired a 75% interest in Harrison Street earlier this year. Mr. Galvin presently serves as Chairman or board member of Uniquesoft, LLC, Velocidata, evolve24, Three Ocean Partners and MCR-Aerodyne, Inc. Additionally, Mr. Galvin is a member of the Executive Committee of Northwestern University’s Board of Trustees, and the Boards of Trustees of the American Enterprise Institute, the Legion D’honneur, and Tsinghua University School of Economics Management Advisory Council, among others. Mr. Galvin has previously served in a variety of executive leadersh

Seclore Offers the First Open Data-Centric Security Platform24.9.2018 15:00Pressemelding

Easily leverage best-of-breed data protection solutions and existing Enterprise systems for an automation-first approach to data protection and tracking MILPITAS, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Seclore, providers of the industry’s first browser-based Rights Management solution, today announced the release of Seclore’s Data-Centric Security Platform (DCSP). A first-of-its kind platform, it is designed to give customers an open, integrated and automated Data-Centric Security approach to discover, identify, protect and track sensitive data. The automation and agility of the platform enables organizations to remove the limitations of point solutions while increasing the security of sensitive data. At the core of the Seclore DCSP, is the Seclore Unified Policy Manager, the central engine for orchestrating policy management, identity federation, and usage data consolidation. Learn more about the Seclore Data-Centric Security Platform “As data grows exponentially and is stored and

XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa24.9.2018 14:30Pressemelding

AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it had completed enrollment in the U.S. for its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). Enrollment has exceeded the planned limit for the study in just over two months, significantly outpacing expectations. XBiotech plans to accept a limited number of additional patients in Europe prior to study completion. John Simard, Chairman & CEO of XBiotech, commented, “We are very pleased by the enrollment rate we have seen in this study. Patient availability has been well beyond what was predicted. I believe this speaks to the need for new treatment options for this debilitating disease. I want to thank all of the patients and clinical sites for their ongoing participation in this study.” The phase 2 study involves a 13-week treatment regimen. Two groups of patients are being treated

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom